<DOC>
	<DOCNO>NCT02074137</DOCNO>
	<brief_summary>Primary Objective : To evaluate safety cabazitaxel ( Jevtana ) patient metastatic hormone refractory prostate cancer Secondary Objectives : 1 . To describe use cabazitaxel ( Jevtana ) combination oral prednisolone treatment patient metastatic Hormone Refractory Prostate Cancer 2 . To describe patient profile term demography , disease characteristic prior treatment history 3 . To describe efficacy outcome : radiological response ( available ) use Recist criterion V 1.1 Prostate Specific Antigen ( PSA ) response</brief_summary>
	<brief_title>Evaluation Safety Cabazitaxel ( Jevtana ) Patients With Metastatic Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>The study consist : - screen phase ( maximum length 7-day ) . - treatment phase 21-day study treatment cycle . Patients continue receive treatment disease progression , death , unacceptable toxicity , investigator 's decision withdrawal consent . - 30-day follow-up visit last dose study medication .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>Inclusion criterion : Metastatic hormone refractory prostate cancer ( mHRPC ) previously treat docetaxelcontaining regimen Disease Progression docetaxelcontaining regimen mHRPC Surgical medical castration Patient ≥ 18 year ≤ 75 year age Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Adequate bone marrow , liver , renal function : Neutrophils &gt; 1500 /mm3 ; Hemoglobin &gt; 10 g/dL ; Platelets &gt; 100 x109/L ; Bilirubin &lt; Upper Normal Limit ( ULN ) ; Serum Glutamate Oxaloacetate Transaminase ( Aspartate Aminotransferase ) /SGOT ( AST ) &lt; 1.5xULN ; Serum Glutamate Pyruvate Transaminase ( Alanine Aminotransferase ) /SGPT ( ALT ) &lt; 1.5xULN ; Creatinine &lt; 1.5xULN . In case creatinine &gt; 1.0 x ULN &lt; = 1.5 x ULN , calculate creatinine clearance accord CKDEPI formula &gt; = 60 ml/min . Written informed consent must obtain prior study related procedure Exclusion criterion : Prior radiotherapy ≥ 40 % bone marrow Previous treatment cabazitaxel ( Jevtana® ) Prior surgery , radiation , chemotherapy , anticancer therapy within 4 week prior enrollment Active grade ≥2 peripheral neuropathy Active grade ≥2 stomatitis Active infection require systemic antibiotic antifungal medication Active cancer ( mHRPC ) include prior malignancy patient diseasefree ≤5 year Known brain leptomeningeal involvement History severe hypersensitivity reaction ( ≥grade 3 ) docetaxel History severe hypersensitivity reaction ( ≥grade 3 ) polysorbate 80 contain drug History severe hypersensitivity reaction ( ≥grade 3 ) intolerance prednisone prednisolone Uncontrolled severe illness medical condition ( include uncontrolled diabetes mellitus ) Concurrent plan treatment strong inhibitor strong inducer cytochrome P450 3A4/5 ( 2 week washout period necessary patient already treatment ) . Participation clinical trial investigational drug Patient reproductive potential implementing accept effective method contraception The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>